**MTP: Annual General Mandate 2024**

On April 22, 2024, Medipharco Pharmaceutical Joint Stock Company announced General Mandate as follows:

Article 1. Approve the content of reports presented at the Meeting:

1.1/ Report of the General Manager and Chair of the Board of Directors on production - business performance results of the Company in 2023 and production - business plan in 2024 (Attached Report):

a/ Report on targets for implementing the plan in 2023:

* Sales in 2023 reached VND 1,248.3 billion (rounded number), reaching 127% of the plan in 2023.

b/ Profit according to audit results in 2023:

* Profit before tax: VND 20,095,838,640
* Profit after tax: VND 16,020,505,117

c/ The General Meeting of Shareholders unanimously approved the goals, targets, and tasks of 2024 (Attached Report), which are:

C1.Continue main goals, sustainable development goals and medium and long-term development strategy of the Company: According to approved goals and strategies of the Board of Directors in the term 4 (2020-2025).

C2. Implement sustainable development goals:

* Continue to invest in business development to meet the development strategy of Vietnam's Pharmaceutical Industry. Implement the general goals of Vietnam's Pharmaceutical Industry are: Build Vietnam's Pharmaceutical Industry to develop on a par with advanced countries in the region and the world, focusing on developing the Pharmaceutical Industry in a modern direction, towards the production of invented drugs and drugs with modern dosage forms. At the same time, ensure the consistent goal of providing adequate and timely medicines with guaranteed quality, reasonable prices, safety and effectiveness to serve the people's disease prevention and treatment needs.
* Continue to build, strengthen and develop the Company's brand "MEDIPHARCO".
* Continue to build & implement product strategies, strengthen cooperation in research and development of production and business with new active ingredients in disease treatment, drugs with new preparation technology suitable for existing production lines and technology of the Company.
* Continue to invest in machinery and equipment for production, quality control, research, preservation and upgrading of air conditioning systems and aseptic factories to meet the needs of developing manufactured goods and increasing production capacity up to 40 million converted products; Meet the management and maintenance of quality according to GPs update standards;
* Focus on developing medicine production, contributing to increasing the value of industrial production output, attracting workers from society; Contribute to the care and protection of community health, and develop the Vietnamese Pharmaceutical Industry. Continue to build & implement product strategies, strengthen cooperation in research and development of production and business with new active ingredients in disease treatment, drugs with new preparation technology suitable for existing production lines and technology of the Company.
* Business development goes hand in hand with implementing environmental protection solutions
* Cooperate to expand export markets in African countries; Southeast Asia; Western Asia.... Maintain and increase export turnover to at least USD 2 million /year
* Invest in a Land Lease Project to develop a farming and processing farm for medicinal herbs according to GACP -WH0 standards in Hue Province.
* Adjust the Investment Certificate, prepare a feasibility report, submit to the General Meeting of Shareholders for approval the project of building a drug storage warehouse according to GSP standards in Phu Bai Industrial Park to meet the goal of increasing production capacity to 40 million products and meeting conditions for import-export and preservation services.

C3. Overall plan targets for 2024:

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Target | Unit  | 2024 Plan  |
| A | Total revenue | Billion VND  | 984 |
| I/ | Manufactured Goods:  |  | 324 |
|  | Total converted products | Million Products  | 40 |
| II/ | Business Goods  |  | 660 |
| B- | Profit before tax:  | Billion VND  |  |
|  | In case of warehouse investment that has not yet been put into use, accounting and interest payments on investment loans will be made in 2024 | Billion VND  | 22.295 |
|  | In case the warehouse investment is completed, put into use and accounted for, investment loan interest will be paid in 2024 | Billion VND  | 15.295 |
| C- | Current corporate tax:  | Billion VND  | 3.059 |
| D- | Profit after tax:  | Billion VND  |  |
|  | In case of warehouse investment that has not yet been put into use, accounting and interest payments on investment loans will be made in 2024 | Billion VND  | 17.800 |
|  | In case the warehouse investment is completed, put into use and accounted for, investment loan interest will be paid in 2024 | Billion VND  | 10.500 |
| E | Expected dividend | % | 10% |
| G- | Charter capital:  |  | 74.554 |
| H- | Investment plan  | Billion VND  | 72.8 |
| H1 | Plan in 2023 has been approved for transition to 2024  | Billion VND  | 12.9 |
| H2 | New investment in 2024 | Billion VND  | 59.977 |
| a) | Investment  | Billion VND  | 19.977 |
| b) | Phu Bai Medicine Warehouse | Billion VND  | 40 |

C4. Carry out the implementation of General Mandates

1.2/ Approve the Audited Public Financial Statements 2023 and comments as per the Meeting Minutes

1.3/ Approve the report of the Supervisory Board on results of production and business activities of the Company in 2023 and the operation direction of the Supervisory Board in 2024 and comments as per the Meeting Minutes.

1.4/ Approve Proposals presented at the General Meeting of Shareholders 2024 as follows:

1. Proposal on approving Reports presented at the Annual General Meeting of Shareholders:
2. Proposal on the profit distribution plan in 2023;

Detailed proposal and Minutes of the Annual General Meeting of Shareholders 2023 are attached.

The dividend rate in 2023 was 10%

* The Board of Directors would like to submit to the Annual General Meeting of Shareholders 2024 to approve the content of profit distribution in 2023

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| No. | Target | Unit | Expected (VND)  | Note |
| 1 | Profit after tax in 2023 (audited) | VND | 16,020,505,117 |  |
| 2 | Remaining profit to be distributed | VND | 16,020,505,117 |  |
| 3 | Dividends payment in cash: | 10% | 7,450,806,000 | Does not include 4,600 treasury shares; Par value of VND 10,000 /share |
| 4 | Total number of shares for which dividends are paid | Share | 7,450,806 | Current shares |
| 4 | Bonus for the Board of Directors - Supervisory Board - Accounting - General Manager | 3% | 480,615,154 | Assign the Board of Directors to decide |
| 5 | Remaining profits distributed to funds: | VND | 8,089,083,963 |  |
| 5.7 | Investment and Production Development Fund: | 90% | 7,280,175,567 |  |
| 5.2 | Welfare fund: | 10% | 808,908,396 |   |

1. Proposal on the selection of an audit company for 2024

Detailed proposal and Minutes of the Annual General Meeting of Shareholders 2024 are attached.

1. Proposal on the remuneration for the Board of Directors and the Supervisory Board in 2024
2. Proposal on approving the GSP drug warehouse investment project in Phu Bai Industrial Park:

Article 2: Terms of enforcement:

This General Mandate takes effect from April 22, 2024 after the Annual General Meeting of Shareholders 2024 of Medipharco Pharmaceutical Joint Stock Company approved.

The General Meeting of Shareholders assigns the Board of Directors and the Supervisory Board to take responsible for directing and organizing the implementation of this General Mandate.